

30 September 2010

Proposal relating to calcium folinate, methotrexate, paclitaxel, epirubicin, carboplatin, oxaliplatin and fludarabine

Following a request to pharmaceutical suppliers for commercial proposals as an alternative to tendering certain pharmaceuticals for sole supply, PHARMAC and InterPharma Pty Limited have entered into a provisional agreement relating to the supply of the Ebewe brands of calcium folinate, methotrexate, paclitaxel, epirubicin, carboplatin, oxaliplatin and fludarabine.

We are now seeking feedback on this proposal. In summary, the proposal would result in:

- awarding Hospital Supply Status from 1 December 2010 to 30 June 2014 to the Ebewe brands of calcium folinate injection, methotrexate injection and paclitaxel injection;
- listing Fludarabine Ebewe (fludarabine phosphate injection 50 mg) from 1 July 2011;
- awarding Hospital Supply Status to Fludarabine Ebewe from 1 September 2011 to 30 June 2014; and
- a reduction in the price and subsidy of the currently listed Ebewe brands of epirubicin, carboplatin and oxaliplatin injections.

Further details of the proposal can be found on the following pages.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **5 pm, Thursday 14 October 2010** to:

Sue Anne Yee
Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: sueanne.yee@pharmac.govt.nz

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposal

PHARMAC has reached a provisional agreement with Interpharma Limited for supply of the Ebewe brand of calcium folinate, methotrexate, paclitaxel, epirubicin, carboplatin, oxaliplatin and fludarabine. We are now seeking feedback on this proposal. Details of the proposal are as follows:

Calcium Folate

- From 1 December 2010 the prices and subsidies for calcium folinate (Calcium Folate Ebewe) in Section B and Part II of Section H of the Pharmaceutical Schedule would be amended as follows:

Pharmaceutical	Brand	Presentation	Pack size	Current Price and Subsidy	Price and Subsidy from 1 December 2010
Calcium folinate	Calcium Folate Ebewe	Inj 50 mg	5	\$24.50	\$24.50
Calcium folinate	Calcium Folate Ebewe	Inj 100 mg	1	\$9.75	\$9.75
Calcium folinate	Calcium Folate Ebewe	Inj 300 mg	1	\$30.00	\$30.00
Calcium folinate	Calcium Folate Ebewe	Inj 1g	1	\$100.00	\$90.00
Calcium folinate	Calcium Folate Ebewe	Inj 1 mg for ECP	1 mg	\$0.10	\$0.10

- The inj 50 mg, 100mg, 300 mg and 1g presentations of Calcium Folate Ebewe would have Hospital Supply Status until 30 June 2014;

Methotrexate

- From 1 December 2010 the prices and subsidies for methotrexate (Methotrexate Ebewe) in Section B and Part II of Section H of the Pharmaceutical Schedule would be amended as follows:

Pharmaceutical	Brand	Presentation	Pack size	Current Price and Subsidy	Price and Subsidy from 1 December 2010
Methotrexate	Methotrexate Ebewe	Inj 100 mg per ml, 10 ml	1	\$27.50	\$25.00
Methotrexate	Methotrexate Ebewe	Inj 100 mg per ml, 50 ml	1	\$135.00	\$125.00
Methotrexate	Methotrexate Ebewe	Inj 1 mg for ECP	1 mg	\$0.10	\$0.09
Methotrexate	Methotrexate Ebewe	Inj 5 mg intrathecal syringe for ECP	5 mg OP	\$4.73	\$4.73

- The inj 100 mg per ml, 10 ml and 100 mg per ml, 50 ml presentations of Methotrexate Ebewe would have Hospital Supply Status until 30 June 2014;

Paclitaxel

- From 1 December 2010 the prices and subsidies for paclitaxel (Paclitaxel Ebewe) in Section B and Part II of Section H of the Pharmaceutical Schedule would be amended as follows:

Pharmaceutical	Brand	Presentation	Pack size	Current Price and Subsidy	Price and Subsidy from 1 December 2010
Paclitaxel	Paclitaxel Ebewe	Inj 30 mg	5	\$189.75	\$137.50
Paclitaxel	Paclitaxel Ebewe	Inj 100 mg	1	\$125.35	\$91.67
Paclitaxel	Paclitaxel Ebewe	Inj 150 mg	1	\$188.03	\$137.50
Paclitaxel	Paclitaxel Ebewe	Inj 300 mg	1	\$376.50	\$275.00
Paclitaxel	Paclitaxel Ebewe	Inj 600 mg	1	\$724.50	\$550.00
Paclitaxel	Paclitaxel Ebewe	Inj 1 mg for ECP	1 mg	\$1.32	\$1.02

- The inj 30 mg, 100mg, 150 mg, 300 mg and 600 mg presentations of Paclitaxel Ebewe would have Hospital Supply Status until 30 June 2014;

Epirubicin

- From 1 December 2010 the prices and subsidies for epirubicin (Epirubicin Ebewe) in Section B and Part II of Section H of the Pharmaceutical Schedule would be amended as follows:

Pharmaceutical	Brand	Presentation	Pack size	Current Price and Subsidy	Price and Subsidy from 1 December 2010
Epirubicin	Epirubicin Ebewe	Inj 2 mg per ml, 5 ml	1	\$25.00	\$25.00
Epirubicin	Epirubicin Ebewe	Inj 2 mg per ml, 25 ml	1	\$87.50	\$87.50
Epirubicin	Epirubicin Ebewe	Inj 2 mg per ml, 50 ml	1	\$155.00	\$125.00
Epirubicin	Epirubicin Ebewe	Inj 2 mg per ml, 100 ml	1	\$310.00	\$210.00
Epirubicin	Epirubicin Ebewe	Inj 1 mg for ECP	1 mg	\$1.90	\$1.80

- The inj 2 mg per ml, 5 ml, inj 2 mg per ml, 25 ml, inj 2 mg per ml, 50 ml and inj 2 mg per ml, 100 ml presentations of Epirubicin Ebewe would continue to have Hospital Supply Status until 30 June 2012;

Carboplatin

- From 1 December 2010 the prices and subsidies for carboplatin (Carboplatin Ebewe) in Section B and Part II of Section H of the Pharmaceutical Schedule would be amended as follows:

Pharmaceutical	Brand	Presentation	Pack size	Current Price and Subsidy	Price and Subsidy from 1 December 2010
Carboplatin	Carboplatin Ebewe	Inj 10 mg per ml, 5 ml	1	\$20.00	\$20.00
Carboplatin	Carboplatin Ebewe	Inj 10 mg per ml, 15 ml	1	\$22.50	\$22.50
Carboplatin	Carboplatin Ebewe	Inj 10 mg per ml, 45 ml	1	\$55.00	\$50.00
Carboplatin	Carboplatin Ebewe	Inj 10 mg per ml, 100 ml	1	\$120.00	\$105.00
Carboplatin	Carboplatin Ebewe	Inj 1 mg for ECP	1 mg	\$0.15	\$0.15

- The inj 10 mg per ml, 5 ml, inj 10 mg per ml, 15 ml, inj 10 mg per ml, 45 ml and inj 10 mg per ml, 100 ml presentations of Carboplatin Ebewe would continue to have Hospital Supply Status until 30 June 2012;

Oxaliplatin

- From 1 December 2010 the prices and subsidies for oxaliplatin (Oxaliplatin Ebewe) in Section B and Part II of Section H of the Pharmaceutical Schedule would be amended as follows:

Pharmaceutical	Brand	Presentation	Pack size	Current Price and Subsidy	Price and Subsidy from 1 December 2010
Oxaliplatin	Oxaliplatin Ebewe	Inj 50 mg	1	\$65.00	\$55.00
Oxaliplatin	Oxaliplatin Ebewe	Inj 100 mg	1	\$130.00	\$110.00
Oxaliplatin	Oxaliplatin Ebewe	Inj 1 mg for ECP	1 mg	\$1.42	\$1.20

- The inj 50 mg and inj 100 mg presentations of Oxaliplatin Ebewe would continue to have Hospital Supply Status until 30 June 2012.

Fludarabine

- Fludarabine phosphate injection 50 mg (Fludarabine Ebewe) would be listed in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 July 2011 at the following price and subsidy:

Pharmaceutical	Brand	Presentation	Pack size	Price and Subsidy
Fludarabine phosphate	Fludarabine Ebewe	Inj 50 mg	5	\$525.00

- The above presentation of Fludarabine Ebewe would have Hospital Supply Status from 1 September 2011 until 30 June 2014.
- The currently listed Fludara brand of fludarabine phosphate inj 50 mg would be delisted from Part II of Section H of the Pharmaceutical Schedule from 1 September 2011.
- The price and subsidy of fludarabine inj 50 mg for ECP (Baxter) would be reduced from \$286.00 to \$105.00 per 50 mg OP in Section B of the Pharmaceutical Schedule from 1 September 2011.